PUBLISHER: The Business Research Company | PRODUCT CODE: 1957772
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957772
A sedative-hypnotic drug is a chemical substance used to reduce tension and anxiety, induce a feeling of calm (sedative effect), or assist in initiating sleep (hypnotic effect). These drugs work by suppressing the limbic system of the brain, which controls emotional and behavioral responses, as well as the reticular formation, which regulates sleep patterns and overall consciousness.
The primary categories of sedative-hypnotic drugs include benzodiazepines, barbiturates, antihistamines, nonbenzodiazepines, and others. Benzodiazepines are a class of medications that reduce activity in the brain and nervous system and are used to relieve symptoms of anxiety and insomnia due to their calming effects on the central nervous system. They can be administered via multiple routes, including oral, parenteral, and others, to treat various conditions such as sleep disorders, anesthesia, pain, and more. These medications are distributed through different channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, to a range of end-users, including hospitals, specialty clinics, home care, and beyond.
Tariffs have impacted the sedative-hypnotic drugs market by increasing costs associated with imported active pharmaceutical ingredients and formulation excipients, particularly affecting benzodiazepines and nonbenzodiazepine segments. These effects are more pronounced in regions reliant on international pharmaceutical supply chains, including parts of Asia-Pacific and Latin America. Higher tariffs can lead to elevated drug prices and supply delays in hospital and retail pharmacies. Conversely, tariffs have encouraged local manufacturing and generic drug production, improving supply security and reducing long-term dependence on imports.
The sedative-hypnotic drugs market research report is one of a series of new reports from The Business Research Company that provides sedative-hypnotic drugs market statistics, including sedative-hypnotic drugs industry global market size, regional shares, competitors with a sedative-hypnotic drugs market share, detailed sedative-hypnotic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the sedative-hypnotic drugs industry. This sedative-hypnotic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sedative-hypnotic drugs market size has grown strongly in recent years. It will grow from $3.86 billion in 2025 to $4.18 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to high prevalence of sleep disorders, widespread use of benzodiazepines in anxiety treatment, increased surgical procedures requiring anesthesia, rising stress-related disorders, availability of low-cost generic sedatives.
The sedative-hypnotic drugs market size is expected to see strong growth in the next few years. It will grow to $5.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing incidence of insomnia and sleep disorders, increasing aging population, rising demand for safer long-term sleep medications, expansion of nonbenzodiazepine drug classes, greater awareness of mental health conditions. Major trends in the forecast period include growing shift toward nonbenzodiazepine sleep aids, rising preference for short-acting sedative formulations, increasing focus on reduced dependency and abuse potential, expansion of home-based sleep disorder management, greater emphasis on safety profiles in chronic use.
The increasing stress levels are anticipated to drive the expansion of the sedative-hypnotic drugs market in the coming years. Stress is defined as the emotional or mental strain caused by demanding or unpredictable situations, including economic difficulties, workplace pressures, political instability, and wider social or psychological challenges. The rise in stress levels can be attributed to factors such as financial uncertainty, heightened job demands, and prolonged societal disruptions, which together have led to increased emotional strain among adults. Sedative-hypnotic drugs aid mental well-being by alleviating anxiety, promoting relaxation, and enhancing sleep quality, thereby addressing the growing stress burden faced by individuals. For example, in May 2024, the American Psychiatric Association, a U.S.-based organization, reported that 43% of U.S. adults felt more anxious than they had the previous year, up from 37% in 2023 and 32% in 2022, highlighting an upward trend in anxiety levels. Consequently, the rising stress levels are contributing to the growth of the sedative-hypnotic drugs market.
The growing geriatric population is anticipated to drive the expansion of the sedative-hypnotic drugs market in the coming years. The geriatric population refers to individuals typically aged 65 years and older, encompassing older adults who may have distinct healthcare, social, and physiological needs associated with aging. The rise in the geriatric population is mainly due to increased life expectancy, which allows more people to live longer because of improved healthcare, better disease management, and enhanced living conditions. Sedative-hypnotic drugs support the geriatric population by enhancing sleep quality, reducing nighttime agitation, and promoting overall cognitive and physical well-being in older adults. For example, in July 2024, according to the UK Parliament's House of Commons Library, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is expected to increase to 22.1 million by 2072, accounting for 27% of the population. Therefore, the growing geriatric population is contributing to the expansion of the sedative-hypnotic drugs market.
Major companies in the sedative-hypnotic drugs market are concentrating on developing innovative approaches such as next-generation insomnia therapies to enhance sleep quality and safety. Next-generation insomnia therapies are advanced treatments aimed at improving sleep quality and safety by targeting specific sleep mechanisms while minimizing side effects compared to traditional sedative-hypnotics. For example, in June 2025, Simcere Pharmaceutical Group Limited, a China-based biopharmaceutical company, collaborated with Idorsia Ltd., a Switzerland-based biopharmaceutical company, to introduce QUVIVIQ (Daridorexant Hydrochloride Tablets), an anti-insomnia medication, to the Chinese market. The drug was later approved by the National Medical Products Administration (NMPA) for treating adult patients with insomnia characterized by difficulty falling asleep and maintaining sleep. Importantly, QUVIVIQ is not classified as a psychotropic drug, providing a treatment option without the regulatory restrictions commonly associated with sedative-hypnotic medications.
Major companies operating in the sedative-hypnotic drugs market are Pfizer Inc., Sun Pharmaceutical Industries Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi-Aventis AG, AstraZeneca Plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Teva Pharmaceutical Industries Ltd., Mylan N.V., Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Pharmaceuticals Inc., Glenmark Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Abbott Laboratories
North America was the largest region in the sedative-hypnotic drugs market in 2025. The regions covered in the sedative-hypnotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the sedative-hypnotic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The sedative-hypnotic drugs market consists of sales of tablets, capsules, injectables, and liquid formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Sedative-Hypnotic Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses sedative-hypnotic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for sedative-hypnotic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sedative-hypnotic drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.